Fate Therapeutics, Inc. (FATE)
0.919
-0.09
(-9.01%)
USD |
NASDAQ |
Nov 20, 16:00
0.965
+0.05
(+5.01%)
After-Hours: 20:00
Fate Therapeutics Research and Development Expense (TTM) : 87.29M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 87.29M |
| June 30, 2026 | 88.36M |
| March 31, 2026 | 90.91M |
| December 31, 2025 | 94.93M |
| September 30, 2025 | 101.36M |
| June 30, 2025 | 108.79M |
| March 31, 2025 | 114.52M |
| December 31, 2024 | 116.04M |
| September 30, 2024 | 114.17M |
| June 30, 2024 | 113.67M |
| March 31, 2024 | 120.19M |
| December 31, 2023 | 154.31M |
| September 30, 2023 | 209.73M |
| June 30, 2023 | 256.82M |
| March 31, 2023 | 298.76M |
| December 31, 2022 | 306.70M |
| September 30, 2022 | 291.66M |
| June 30, 2022 | 266.64M |
| March 31, 2022 | 235.15M |
| December 31, 2021 | 209.67M |
| September 30, 2021 | 180.48M |
| June 30, 2021 | 158.79M |
| March 31, 2021 | 137.86M |
| December 31, 2020 | 122.54M |
| September 30, 2020 | 109.00M |
| Date | Value |
|---|---|
| June 30, 2020 | 101.70M |
| March 31, 2020 | 97.40M |
| December 31, 2019 | 86.12M |
| September 30, 2019 | 75.30M |
| June 30, 2019 | 66.01M |
| March 31, 2019 | 60.92M |
| December 31, 2018 | 54.82M |
| September 30, 2018 | 50.65M |
| June 30, 2018 | 45.66M |
| March 31, 2018 | 36.82M |
| December 31, 2017 | 33.39M |
| September 30, 2017 | 29.82M |
| June 30, 2017 | 28.07M |
| March 31, 2017 | 26.92M |
| December 31, 2016 | 25.57M |
| September 30, 2016 | 24.77M |
| June 30, 2016 | 23.00M |
| March 31, 2016 | 21.14M |
| December 31, 2015 | 19.30M |
| September 30, 2015 | 17.82M |
| June 30, 2015 | 16.97M |
| March 31, 2015 | 16.11M |
| December 31, 2014 | 15.94M |
| September 30, 2014 | 15.10M |
| June 30, 2014 | 14.51M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| AVITA Medical, Inc. | 21.10M |
| Agenus, Inc. | 45.74M |
| Amgen, Inc. | 7.849B |
| Anika Therapeutics, Inc. | 28.40M |
| BioCryst Pharmaceuticals, Inc. | 209.16M |